Temperature excursion: difference between revisions
Diff·revision 22 → 23·21:18, 18 Dec 2025
Difference between revision 22 and revision 23 of Temperature excursion. 12 lines changed; the page grew by 1,842 bytes.
| Revision 22 — 02:02, 5 Dec 2025 CrudePeptidePearl (talk) rm the vendor-specific packaging detail; not general enough for the article 20,277 bytes +585 | Revision 23 — 21:18, 18 Dec 2025 FmocFrancis (talk) give the vial sizes in millilitres of nominal capacity 22,119 bytes +1,842 | ||
|---|---|---|---|
| 128 | Two structural features of this sequence are worth noting. It is asymmetric in favour of rejection, because the burden is to show that quality is unaffected rather than to show that it is affected. And it depends at step 4 on data that exist only for products with a stability programme, which is why the sequence cannot be applied outside regulated distribution however carefully the temperature was recorded.{{r|ich_q1a}} | 128 | Two structural features of this sequence are worth noting. It is asymmetric in favour of rejection, because the burden is to show that quality is unaffected rather than to show that it is affected. And it depends at step 4 on data that exist only for products with a stability programme, which is why the sequence cannot be applied outside regulated distribution however carefully the temperature was recorded.{{r|ich_q1a}} |
| 129 | 129 | ||
| + | 130 | === What a stability-indicating assay is asked to demonstrate === | |
| + | 131 | A ''stability-indicating'' method is one shown to resolve the intact substance from its degradation products, so that a change in the assay result can be attributed to degradation rather than to variability. Demonstrating that property is a validation exercise, and the demonstration is conventionally made by forced degradation: the substance is deliberately stressed by heat, humidity, acid, base, oxidant and light, and the method is shown to separate and quantify what results, with mass balance accounted for.{{r|ich_q1a,manning2010}} | |
| + | 132 | ||
| + | 133 | After an excursion, such a method is asked to answer a narrow set of questions: | |
| + | 134 | ||
| + | 135 | * has the assay value for the intact peptide fallen relative to the pre-excursion result for the same lot; | |
| + | 136 | * have known degradation products increased, and specifically those expected from the stress applied — deamidation products after warm aqueous exposure, oxidation products after oxygen exposure, aggregate after freezing; | |
| + | 137 | * has any new peak appeared that was not present before and is not attributable to the method; | |
| + | 138 | * do orthogonal methods agree, since a single chromatographic method may be blind to a physical change that a size-exclusion or particulate method detects.{{r|manning2010}} | |
| + | 139 | ||
| + | 140 | Two limitations are structural. Without a pre-excursion result for the same lot, a purity figure establishes only the current state, not a change; the retained sample is therefore the critical asset, and its absence is what most often makes a post-hoc assessment impossible. And a method's limit of detection sets a floor below which no statement can be made: an assay resolving 0.1% of a degradation product cannot demonstrate the absence of 0.05%, and a report of no detected change means no change above that floor rather than no change.{{r|ich_q1a}} | |
| + | 141 | ||
| 130 | == References == | 142 | == References == |
| 131 | {{reflist}} | 143 | {{reflist}} |